Renalase Concentration Research Articles

Effect of Renal Denervation on Plasma Renalase Concentration in Patients with Resistant Hypertension

Effect of Renal Denervation on Plasma Renalase Concentration in Patients with Resistant Hypertension

Cardiovascular Risk in Pediatric Renal Transplant Recipients.

The survival of pediatric chronic kidney disease (CKD) patients has improved in recent decades due to advances in dialysis and transplantation. However, cardiovascular disease (CVD) emerges as the main cause of mortality in patients with CKD. To estimate cardiovascular risk in children with CKD at least 1 year after kidney transplantation. In addition, the possible association of cardiovascular risk with classic biochemical markers and potential new markers of this outcome was investigated. An observational ambidirectional (retrospective capture of risk factors and prospective study of outcomes) research including 75 patients who underwent renal transplant between 2003 and 2013 with postoperative follow-up of at least 1 year was conducted. The outcome variables adopted were the LV mass Z-score and the presence of coronary calcification on computed tomography using calcium Agatston score. Only one patient had an elevated calcium score, and three children (4%) had an LV mass Z-score ≥ 2.0. After multivariable analysis, only gender, serum triglyceride, and serum renalase concentration remained significantly associated with LV mass. The low incidence of cardiovascular changes in the population studied confirms the benefit of transplantation for the cardiovascular health of children. Nevertheless, long-term follow-up of these patients is recommended, given the limited duration of kidney function provided by transplantation and the high likelihood of further dialysis and kidney transplants being required in these children.

Relation Between Exposure to Tobacco Smoke Assessed by Serum Cotinine Concentration and Questionnaire Method, and Serum Renalase Concentration—the Importance of the Coexistence of Arterial Hypertension and Other Cardiovascular Diseases

Exposure to tobacco smoke (ETS) is one of the main risk factors for cardiovascular disease (CVD). Renalase is a protein that may play a role in the pathogenesis of CVD. The aim of the study was to assess the relationship between ETS and serum renalase concentration. A group of 109 patients was recruited for this study (49.7 ± 14.7 years). In accordance with the questionnaire, patients were divided into the following subgroups: subgroup A– declaring themselves active smokers (n = 36), subgroup B– declaring themselves non-smokers and exposed to environmental tobacco smoke (n = 35), subgroup C– declaring themselves non-smokers and not exposed to environmental tobacco smoke (n = 38). The same patients were divided based on cotinine concentration into the following subgroups: subgroup D– active smokers (n = 42), subgroup E– non-smokers exposed to environmental tobacco smoke (n = 66), and subgroup F– non-smokers not exposed to environmental tobacco smoke (n = 1). Serum cotinine concentration and serum renalase concentration were measured using ELISA tests. Serum renalase concentration was statistically significantly higher in subgroup C than in subgroups A and B and in subgroup E and F than in D. There was a negative correlation between serum cotinine concentration and serum renalase concentration (r = −0.41, p < 0.05). Regression analysis showed that higher BMI, higher diastolic blood pressure, coronary artery disease and higher serum cotinine concentration are independent risk factors of lower serum renalase concentration. The questionnaire method of assessing exposure to tobacco smoke was characterized by high sensitivity, but only moderate specificity, especially in terms of assessing environmental exposure to tobacco smoke. In summary, the study showed an independent relationship between exposure to tobacco smoke and lower serum renalase concentration.

The Discriminatory Ability of Renalase and Biomarkers of Cardiac Remodeling for the Prediction of Ischemia in Chronic Heart Failure Patients With the Regard to the Ejection Fraction.

Background: Renalase has been implicated in chronic heart failure (CHF); however, nothing is known about renalase discriminatory ability and prognostic evaluation. The aims of the study were to assess whether plasma renalase may be validated as a predictor of ischemia in CHF patients stratified to the left ventricular ejection fraction (LVEF) and to determine its discriminatory ability coupled with biomarkers representing a range of heart failure (HF) pathophysiology: brain natriuretic peptide (BNP), soluble suppressor of tumorigenicity (sST2), galectin-3, growth differentiation factor 15 (GDF-15), syndecan-1, and cystatin C.Methods: A total of 77 CHF patients were stratified according to the LVEF and were subjected to exercise stress testing. Receiver operating characteristic curves were constructed, and the areas under curves (AUC) were determined, whereas the calibration was evaluated using the Hosmer-Lemeshow statistic. A DeLong test was performed to compare the AUCs of biomarkers.Results: Independent predictors for ischemia in the total HF cohort were increased plasma concentrations: BNP (p = 0.008), renalase (p = 0.012), sST2 (p = 0.020), galectin-3 (p = 0.018), GDF-15 (p = 0.034), and syndecan-1 (p = 0.024), whereas after adjustments, only BNP (p = 0.010) demonstrated predictive power. In patients with LVEF <45% (HFrEF), independent predictors of ischemia were BNP (p = 0.001), renalase (p < 0.001), sST2 (p = 0.004), galectin-3 (p = 0.003), GDF-15 (p = 0.001), and syndecan-1 (p < 0.001). The AUC of BNP (0.837) was statistically higher compared to those of sST2 (DeLong test: p = 0.042), syndecan-1 (DeLong: p = 0.022), and cystatin C (DeLong: p = 0.022). The AUCs of renalase (0.753), galectin-3 (0.726), and GDF-15 (0.735) were similar and were non-inferior compared to BNP, regarding ischemia prediction. In HFrEF patients, the AUC of BNP (0.980) was statistically higher compared to those of renalase (DeLong: p < 0.001), sST2 (DeLong: p < 0.004), galectin-3 (DeLong: p < 0.001), GDF-15 (DeLong: p = 0.001), syndecan-1 (DeLong: p = 0.009), and cystatin C (DeLong: p = 0.001). The AUC of renalase (0.814) was statistically higher compared to those of galectin-3 (DeLong: p = 0.014) and GDF-15 (DeLong: p = 0.046) and similar to that of sST2. No significant results were obtained in the patients with LVEF >45%.Conclusion: Plasma renalase concentration provided significant discrimination for the prediction of ischemia in patients with CHF and appeared to have similar discriminatory potential to that of BNP. Although further confirmatory studies are warranted, renalase seems to be a relevant biomarker for ischemia prediction, implying its potential contribution to ischemia-risk stratification.

Associations between renalase concentration and the occurrence of selected diseases.

Renalase is a recently identified flavoprotein oxidase, secreted mainly by the kidneys, which takes part in the degradation of catecholamines. The catecholamine inactivating effect results in the modulation of the sympathetic system tension and, consequently, in a decrease of blood pressure, myocardial contractility, heart rate, and vascular tone. Besides its enzymatic capacity, renalase shows cytoprotective properties by activating mitogen-activated protein kinase (MAPK) pathway. Several single nucleotide polymorphisms (SNPs) of the renalase gene have been identified, of which the most widely studied in relation to the development of selected diseases are rs2296545, rs10887800, and rs2576178. Numerous publications prove the contribution of renalase to the occurrence of cardiovascular diseases, kidney diseases, ischaemic stroke, diabetes type 1 and 2, as well as female infertility and schizophrenia. Further extended research into the various mechanisms of renalase activity may result in the use of this oxidase or its analogues as a therapeutic and/or diagnostic tool.

Renalase and hypertension\u2014demographic and clinical correlates in obstructive sleep apnea

BackgroundRenalase plays an important role in blood pressure regulation. Obstructive sleep apnea (OSA) is a common respiratory disorder associated with hypertension and cardiovascular complications. The aim of the study was to assess the relationship between sleep apnea and renalase concentration.Material and methodsAdult patients (n = 113) were evaluated for OSA in a sleep laboratory using polysomnography. The respiratory events were scored according to the standards developed by the American Academy of Sleep Medicine. The blood renalase concentration was determined by the ELISA (enzyme-linked immunosorbent assay) test.ResultsOSA (AHI ≥ 5) was diagnosed in 71% (n = 80) of the studied population. Renalase concentration was statistically significantly lower in the group with moderate-to-severe OSA (AHI ≥ 15) compared with the group without OSA (AHI < 5) (139.56 ± 175.72 ng/ml vs. 230.97 ± 240.50 ng/ml, p = 0.042). We have found statistically significant negative correlation between renalase and AHI in hypertensives, but not in normotensives. The statistically significant negative correlation was observed between AHI and renalase in the whole studied group, in males, and in the group of age < 60 years old. There was not such a correlation in females and in the group > 60 years old. Based on the regression model, it was shown that lower renalase concentration, hypertension, higher BMI, and male gender are independently associated with higher AHI.ConclusionsThere is a relationship between the blood renalase concentration and the severity of OSA, which may influence hypertension development in OSA.

Moderate-intensity exercise increases renalase levels in the blood and skeletal muscle of rats.

Renalase is predominantly expressed in the kidney, where it plays a role in catecholamine metabolism and blood pressure regulation. Moderate‐intensity exercise (MEX) has been shown to increase the concentration of renalase in the blood and to reduce renal function in humans. Moreover, such exercise was also reported to increase catecholamine levels. Here, we examined renalase concentration in the blood and renalase expression levels in different organs after MEX in rats. Twelve male Wistar rats were made to run on a treadmill (MEX group) for 60 min at 20 m·min−1, after resting for 15 min. The control group rats were euthanized after resting on the treadmill. Tissue and blood samples were analyzed using western blotting, real‐time RT‐PCR and ELISA. Overall, the concentrations of renalase in the blood were significantly higher in the MEX group than that in the control group. Renalase expression was decreased in the kidney after 60 min of exercise, whereas the expression of renalase mRNA and protein in the extensor digitorum longus and plantaris muscles, respectively, increased after exercise. However, the expression of renalase in the other tissues examined did not change after acute exercise. In conclusion, we report that MEX for 60 min increases both renalase concentration in the blood and its expression in skeletal muscle.

The Relationship between Sleep Bruxism Intensity and Renalase Concentration-An Enzyme Involved in Hypertension Development.

Background and objectives: Renalase, a novel amine oxidase, is involved in the development of hypertension. Sleep bruxism (SB) is a sleep-related behavior characterized by rhythmic or non-rhythmic activity of the masticatory muscles, which leads to the mechanical wear of teeth, pain in the masticatory muscles, and disturbed sleep. Recent studies indicate that SB plays a role in increased blood pressure. Therefore, this study aimed to determine the relationship between sleep bruxism intensity and renalase concentration, which may help in the future to elucidate the pathogenesis of hypertension and other cardiovascular disorders. Material and methods: SB was evaluated in 87 adult patients using single-night diagnostic polysomnography with video and audio recordings, and the episodes of bruxism were scored according to the standards of the American Academy of Sleep Medicine. The levels of serum renalase were measured in the patients using enzyme-linked immunosorbent assay kits. Results: SB (Bruxism Episode Index (BEI) ≥2) was diagnosed in 54% (n = 47) of the studied population, and the mean concentration of renalase was found to be decreased in the hypertensive group compared with the normotensive group (133.33 ± 160.71 vs 219.23 ± 220.58, p = 0.047). In addition, a linear negative correlation was observed between the renalase concentration and the body mass index (BMI) in the SB group (r = 0.38, p < 0.05) but not in controls. Thus, higher BEI and higher BMI were identified as factors independently associated with the lower concentration of renalase, but only in the group of patients which had a blood renalase concentration of >212.5 ng/mL. Conclusion: There exists an association between renalase concentration and SB intensity, and further studies are needed to clarify the role of renalase in the pathogenesis of hypertension and other cardiovascular disorders.

Association of Plasma Renalase and Left Ventricle Mass Index in Heart Failure Patients Stratified to the Category of the Ejection Fraction: A Pilot Study.

Heart failure represents a growing health problem, with increasing morbidity and mortality globally. According to the mechanisms involved in the pathogenesis of heart failure, many biomarkers have been proposed for the timely diagnosis and prognostication of patients with heart failure, but other than natriuretic peptides, none of them has gained enough clinical significance. Renalase, a new protein derived from kidneys was demonstrated to metabolize catecholamines and to have a cardioprotective role. The aim of the study was to determine whether renalase and brain natriuretic peptide (BNP) concentration could be used to differentiate heart failure patients stratified to the category of the ejection fraction and whether plasma renalase could be used as a biomarker for left ventricle hypertrophy in all subgroups of heart failure patients. We included patients diagnosed with heart failure and stratified them to the three subgroups according to the ejection fraction. Regarding echocardiographic parameters, HFmrEF had an intermediate profile in between HFrEF and HFpEF, with statistical significance in most evaluated parameters. BNP concentration was significantly different in all three subgroups (p < 0.001), and renalase was statistically higher in HFrEF (p = 0.007) compared to the HFmrEF and HFpEF, where its results were similar, without statistical significance. Renalase plasma concentration was demonstrated to be highly and positively associated with left ventricle mass index in HFrEF (p = 0.029), as well as increased plasma concentration of BNP (p = 0.006). In the HFmrEF group of patients, body mass index was positively associated with LVMI (p = 0.05), while in the patients with HFpEF, diabetes mellitus was demonstrated to have a positive association with LVMI (p = 0.043). These findings suggest that renalase concentration may be measured in order to differentiate patients with reduced ejection fraction. Plasma renalase concentrations positively correlated with left ventricle hypertrophy in patients with reduced ejection fraction, being strongly associated with increased left ventricular mass index.

Direct laboratory evidence that pregnancy-induced hypertension might be associated with increased catecholamines and decreased renalase concentrations in the umbilical cord and mother’s blood

Abstract Background Renalase (RNL) is a controversial enzyme as to whether it oxidizes catecholamines (CAs) (as is generally accepted) in the blood or not. CAs (dopamine [DPMN], epinephrine [EPI] and norepinephrine [NEPI]) are associated with hypertension, including pregnancy-induced hypertension, which occurs in 8–10% of all pregnancies. Therefore, the aim of the study was to compare CAs and renalase concentration in (i) normotensive controls (C), (ii) patients with preeclampsia (PE) and (iii) patients with severe preeclampsia (SPE), which is one of the well-known symptoms of hypertension. Methods This case-control study involved 90 women divided into three groups – 30 C, 30 PE and 30 SPE – whose age and body mass indexes (BMIs) were similar. A total of 270 blood samples (90 maternal samples, 90 umbilical cord artery samples and 90 umbilical cord vein samples) were obtained. CAs and RNL concentrations of the biological samples were measured by enzyme-linked immunosorbent assay (ELISA). Results Comparing the amounts of CAs, RNL and systolic blood pressure (SBP)/diastolic blood pressure (DBP) between healthy control pregnant women and pregnant women with PE and SPE (SBP/DBP was 120/80 mm Hg for C, above 140/90 mm Hg for PE and above 160/110 mm Hg for SPE), the levels of CAs were significantly increased whereas RNL was reduced. The correlation between SBP/DBP and the amount of RNL in pregnant women with PE and SPE was negative. Conclusions These novel results are evidence that hypertension seen in PE and SPE is directly related to increased levels of CAs and reduced RNL concentrations. The use of RNL preparations may be preferred in future to prevent maternal and perinatal morbidity and mortality due to pregnancy-induced hypertension.

Serum Renalase Levels in Adolescents with Primary Hypertension

The prevalence of hypertension in pediatric populations continues to rise. Recent studies suggest that renalase plays an important role in blood pressure regulation. The aim of this study was to evaluate serum renalase concentrations in hypertensive children. This study was a prospective cohort analysis of 88 adolescents (40 girls; 48 boys) aged 11–18 years, divided into two groups: HT—38 subjects with primary hypertension; and R (reference group)—50 subjects with normal blood pressure. Serum renalase concentration was measured using a commercial enzyme-linked immunosorbent assay kit. Hypertensive patients had higher serum renalase levels (median 29.8 µg/mL; Q1–Q3: 26.1–35.8) than the reference group (median 26.8; Q1–Q3: 22.96–29.4, p < 0.01). Serum renalase was strongly related to serum uric acid levels. In hypertensive patients, serum renalase was positively correlated with 24-h systolic blood pressure (SBP) and 24-h diastolic blood pressure (DBP) and with 24-h SBP and 24-h DBP Z-score (LMS). Our results allow us to conclude that serum renalase correlates with blood pressure elevation. Special attention should be drawn to the correlation between renalase and serum uric acid levels not only in hypertensive, but also in normotensive teenagers. Further studies are needed to answer the question of whether increased serum renalase may be a predisposing factor to hypertension in normotensive patients with hyperuricemia.

Renalase is associated with adverse left atrial remodelling and disease burden in patients with atrial fibrillation undergoing pulmonary vein isolation.

Renalase is a catecholamine-metabolising enzyme, but its possible association with atrial fibrillation (AF) remains unknown. We sought to evaluate plasma renalase concentration in patients with AF undergoing pulmonary vein isolation (PVI) with respect to AF clinical characteristics, left atrial (LA) remodelling, and PVI efficacy. This case-control study included 69 patients (median age 58 years) with either paroxysmal (89%) or persistent (11%) AF, referred for PVI, and a control group consisting of 15 patients without AF, matched for age, sex, and comorbidi-ties. An evaluation of transthoracic echocardiography with LA speckle tracking and plasma renalase concentration using an enzyme-linked immunosorbent assay was performed. AF recurrence was defined as any AF episode on seven-day electro-cardiographic monitoring at six-month follow-up. Renalase level was higher in the study group than in the control group (mean 27.99 vs. 21.48 μg/mL, p = 0.004), but it was lower in patients with persistent AF (19.05 vs. 28.77 μg/mL; p = 0.023) and among patients with AF episodes di-rectly preceding PVI (24.50 vs. 29.66 μg/mL; p = 0.04). Renalase concentration within the first quartile was associated with higher mean heart rate (70 vs. 61 bpm, p = 0.029), greater AF burden (36.9% vs. 9.3%, p = 0.027), greater LA diameter (41.1 vs. 37.9 mm, p = 0.011), and a trend towards less negative global LA strain (-9.4 vs. -13.5, p = 0.082). Logistic regres-sion revealed that global four-chamber LA strain was the only independent predictor of renalase variability (p = 0.0045). Renalase concentration did not predict AF recurrence at six-month follow-up (area under curve [AUC] = 0.614, p = 0.216). Low renalase level may be associated with impaired rate control, higher AF burden, and advanced LA remodel-ling in AF patients undergoing PVI, but it does not predict sinus rhythm maintenance.

PP.25.28] RENALASE PLASMA CONCENTRATION BEFORE AND AFTER RADIOFREQUENCY RENAL DENERVATION IN PATIENTS WITH RESISTANT HYPERTENSION

Objective: Renalase is a catecholamine-metabolizing enzyme produced by proximal tubular cells in kidney which is supposed to be involved in blood pressure regulation. The aim of the study was to evaluate plasma renalase concentration before and after radiofrequency renal denervation (RDN) in patients with resistant arterial hypertension. Design and method: 19 patients (10 men, median age 56 (48; 57) years; BMI 30.9 ± 4.4 kg/m2 and eGFR 89 ± 17.7 ml/min/1.73 m2) with resistant hypertension were enrolled in the study. In all patient plasma renalase concentration was measured before and 1, 3, 6 and 12 months after RDN by ELISA method (Cloud-Clone Corp, Houston, USA). Results: A significant decrease of both office systolic and diastolic blood pressure 6 months after RDN was found (192 ± 31 vs. 177 ± 28 mmHg, p = 0.03; 113 ± 23 vs. 99 ± 21 mmHg, p = 0.002, respectively). One and 3 months after RDN plasma renalase concentration decreased significantly (p < 0.05 vs. baseline), with a subsequent return to values comparable with baseline at 6 and 12 months after RDN (NS vs. baseline) (median plasma renalase concentration 22100 vs. 18550 vs. 17600 vs. 20750 vs. 20500 ng/ml, respectively; Friedman analysis of variance p = 0.054). Conclusions: 1. Renal denervation leads to the temporary decrease of plasma renalase concentration in patients with resistant hypertension. 2. Lower plasma renalase concentrations seems to reflect a counteract reaction to blood pressure decline after successful renal denervation.

P2670Plasma renalase concentration in patients with atrial fibrillation undergoing pulmonary vein isolation

P2670Plasma renalase concentration in patients with atrial fibrillation undergoing pulmonary vein isolation

Relationship between microRNA-146a expression and plasma renalase levels in hemodialyzed patients.

BackgroundmicroRNA (miRNA) belongs to the non-coding RNAs family responsible for the regulation of gene expression. Renalase is a protein composed of 342 amino acids, secreted by the kidneys and possibly plays an important role in the regulation of sympathetic tone and blood pressure. The aim of the present study was to investigate plasma renalase concentration, and explore the relationship between miRNA-146a-5p expression and plasma renalase levels in hemodialyzed patients.MethodsThe study population comprised 55 subjects who succumbed to various cardiac events, 27 women and 28 men, aged 65–70 years. The total RNA including miRNA fraction was isolated using QiagenmiRNEasy Serum/Plasma kit according to the manufacturer’s protocol. The isolated miRNAs were analyzed using a quantitative polymerase chain reaction (qRT-PCR) technique. The plasma renalase levels were measured using a commercial ELISA kit.ResultsIn the group of patients with high levels of renalase, higher miRNA-146a expression was found, compared with those with low concentration of renalase. Patients with simultaneous low miRNA-146a expression and high level of renalase were confirmed to deliver a significantly longer survival time compared with other patients.ConclusionsmiRNA-146a and plasma renalase levels were estimated as independent prognostic factors of hemodialyzed patients’ survival time. Patients with low miRNA-146a expression demonstrated a significantly longer survival time in contrast to the patients with a high expression level of miRNA-146a. Moreover, a significantly longer survival time was found in patients with high renalase activity compared with patients with low activity of the enzyme.

Rs10887800 renalase gene polymorphism influences the level of circulating renalase in patients undergoing hemodialysis but not in healthy controls

BackgroundHuman renalase (RNLS), a recently identified flavoprotein with oxidoreductase activity, is secreted into blood by kidneys and metabolizes circulating catecholamines. Recent studies have revealed that common polymorphisms in RNLS gene might affect the risk of several cardiovascular conditions in hemodialyzed patients. However, the exact mechanism underlying this link remains unclear. The study aims to investigate the association between RNLS gene polymorphisms and plasma renalase level in ESKD patients undergoing hemodialysis (HD group) and healthy controls (HC).MethodsA total of 309 hemodialyzed patients and 90 controls were enrolled in the study. All the participants were genotyped for two RNLS SNPs (rs2576178 and rs10887800) using PCR-RFLP method. Plasma renalase concentrations were determined by enzyme-linked immunosorbent assay (USCN Life Science Inc., Wuhan, China). The IBM SPSS Statistics for Windows, version 20 (IBM Corp., Armonk, NY, USA) was used for statistical analyses.ResultsGenotype distribution and allele frequencies of studied SNPs did not differ between two analyzed groups, p > .050. RNLS concentration in HD group (33.54 μg/mL) was significantly higher than in HC (13.16 μg/mL), p < .001. HD patients with rs10887800AA genotype had lower renalase level (29.32 μg/mL) compared to those with AG (34.52 μg/mL), p < .010 and GG genotype (35.91 μg/mL), p < .010. No significant differences in plasma RNLS between rs10887800AG and GG carriers were observed, p > .050. Interestingly, in HC group rs10887800 polymorphism did not influence RNLS concentration. Rs2576178 SNP did not affect the level of plasma RNLS either in HD group or in HC.ConclusionRs10887800 polymorphic variant of RNLS gene influences the level of circulating RNLS in patients undergoing hemodialysis, and thus elucidates the potentially functional relevance of this polymorphism in HD population.

Renalase Assessment With Regard to Kidney Function, Lipid Disturbances, and Endothelial Dysfunction Parameters in Stable Renal Transplant Recipients.

Renal transplant dysfunction has been shown to be independent predictor for premature cardiovascular disease and mortality. Renalase, a flavoprotein secreted by several tissues, including the kidney, has been found to regulate sympathetic tone and blood pressure. The purpose of this secondary analysis was to explore relationships among parameters of endothelial dysfunction, lipids, glomerular filtration rate, and renalase in 2 groups: renal transplant patients with controlled hypertension and healthy volunteers. In the parent study, 73 renal transplant recipients and 32 age- and gender-matched controls were enrolled. A fasting sample for endothelial, lipid, and renalase values, along with other clinical parameters, was obtained. We found statistically significant inverse correlation between renalase and estimated glomerular filtration rate ( r = -0.552, P < .001), positive correlation between renalase and creatinine ( r = 0.364, P = .003), total cholesterol ( r = 0.578, P < .001), low-density lipoprotein cholesterol ( r = 0.261, P = .046), and non-high-density lipoprotein cholesterol ( r = 0.327, P = .01). Renalase inversely correlated with hemoglobin ( r = -0.232, P = .032) and positively with white blood cells ( r = 0.233, P = .032). There was a significant difference in plasma renalase with regard to chronic kidney disease stages ( F = 13.346, P < .001) but did not correlate with C-reactive protein. Renalase did not correlate with any of parameters of endothelial dysfunction, C-reactive protein, neither with some demographic data (gender, age, time or type of transplantation, risk factors). There were no differences in renalase concentration with regard to antihypertensive therapy. Renalase strongly and inversely correlated with kidney function, positively with creatinine and lipid disturbances. Due to that it is very likely that renalase levels are determined mostly by renal function.

Transient changes in serum renalase concentration during long-distance running: The case of an amateur runner under continuous training

Transient changes in serum renalase concentration during long-distance running: The case of an amateur runner under continuous training

Plasma renalase concentration before and after radiofrequency renal denervation in patients with resistant hypertension.

Plasma renalase concentration before and after radiofrequency renal denervation in patients with resistant hypertension

PP.LB02.27

Objective: Renalase is an enzyme that circulates in the blood and modulates the cardiac function, sympathetic tone and systemic blood pressure. It can be synthesized in the kidneys, liver and cardiomyocytes. The active enzyme degrades circulating catecholamines, causing a significant fall in blood pressure. Changes in renalase concentration in hemodialysis patients may explain the frequent occurrence of hypertension among patients with end-stage kidney disease. The aim of this study was to asses’ serum renalase levels in hemodyalisis patients and apparently healthy subjects, and association of renalase and blood pressure in patients group. Design and method: 160 subjects were recruited in the study: 120 with end-stage renal disease, divided into two groups, according to their blood pressures (normotensive and hypertensive), and 40 apparently healthy individuals matched in age and sex. Blood pressure was measured before and after a hemodialysis session. The target values, according to ESH/ESC guidelines, were lower than 140/90 mmHg before, and 130/90 mmHg after hemodialysis. The blood for the estimating serum renalase concentration was taken before dialysis. Enzyme-linked immunosorbent assay (ELISA) kit with monoclonal antibody specific to renalase, was used. Results: Mean serum renalase levels in normotensive as well as hypertensive hemodialysis patients were significantly higher compared to control group {89.32 (45.77–170.22) and 42.7 (32.79–63.35) μg/ml, respectively; p < 0.0005}. No significant difference of renalase levels among normotensive and hypertensive patients was noted {64.04 (40.76–173.84) and 91.86 (56.77–149.75.35)μg/ml; (p > 0.05)}. There was a highly significant difference between systolic and diastolic pressure measured before and after the dialysis in normotensive and hypertensive groups of patients (p < 0.0005). It was noted that there is a significant, negatively directed association between patients’ age at the beginning of dialysis and the duration of hemodialysis. Also, the correlation between blood pressure and renalase activity among normotensive and hypertensive hemodialysis patients was not shown (p > 0.05). Conclusions: Further studies are needed to define the role of renalase and its complex pathophysiological link with blood pressure regulation, kidney function and sympathetic tone. Renalase may become a new therapeutic target that leads to a better prognosis for patients with end-stage kidney disease.